keyword
Keywords chemotherapy versus palliative...

chemotherapy versus palliative care

https://read.qxmd.com/read/38777864/chemotherapy-induced-febrile-neutropenia-fn-healthcare-resource-utilization-hcru-and-costs-in-commercially-insured-patients-in-the-us
#1
JOURNAL ARTICLE
Jeanine A Flanigan, Marie Yasuda, Chi-Chang Chen, Edward C Li
PURPOSE: Febrile neutropenia (FN) is a known side effect of chemotherapy, often requiring hospitalization. Economic burden increases with an FN episode and estimates of cost per episode should be updated from real-world data. METHODS: A retrospective claims analysis of FN episodes in patients with non-myeloid malignancies from 2014 to 2021 was performed in IQVIA PharMetrics® Plus database. FN episodes were defined as having same-day claims for neutropenia and fever or infection, plus antibiotic in outpatient settings, following a claim for chemotherapy; index date was defined as the first claim for neutropenia/fever/infection...
May 23, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38762353/trifluridine-tipiracil-oxaliplatin-%C3%A2-nivolumab-vs-folfox-%C3%A2-nivolumab-in-her2-negative-advanced-oesogastric-adenocarcinoma-the-prodige73-ucgi40-logican-trial
#2
JOURNAL ARTICLE
Damien Botsen, Sylvie Chabaud, Hervé Perrier, Hanifa Ammarguellat, Véronique Jestin-Le-Tallec, Jonathan Olesinski, Clémence Toullec, Thomas Aparicio, Meher Ben Abdelghani, Christophe Borg, Olivier Bouche, Clélia Coutzac, Hervé Devaud, Frédéric Di Fiore, Olivier Dubreuil, Ludovic Evesque, Bruno Huguenin, Marie Muller, Pierre-Guillaume Poureau, Emilie Oularue, David Tougeron, Aziz Zaanan, Samy Ammari, Nicolas De Sousa Carvalho, Pierre Decazes, Christelle De La Fouchardiere
BACKGROUND: Trifluridine/tipiracil (FTD/TPI) is approved in third-line treatment of patients with advanced/metastatic gastric and gastroesophageal junction adenocarcinomas (aGA/GEJA). The association of oxaliplatin with FTD/TPI is promising and the combination of FTD/TPI + oxaliplatin + nivolumab has shown a predictable and manageable safety profile. AIMS: The aim is to evaluate the efficacy and safety of FTD/TPI plus oxaliplatin with or without nivolumab in patients, with HER2 negative aGA/GEJA, unfit for triplet chemotherapy (TFOX/mFLOT regimen), in the first-line metastatic setting in comparison with the standard of care FOLFOX with or without nivolumab...
May 17, 2024: Digestive and Liver Disease
https://read.qxmd.com/read/38761184/clinical-characteristics-and-prognosis-of-patients-with-newly-diagnosed-primary-central-nervous-system-lymphoma-a-multicentre-retrospective-analysis
#3
JOURNAL ARTICLE
Si-Jun Bai, Jian-Xia He, Yuan-Jun Zheng, Ye Geng, Yi-Nan Gao, Cai-Xia Zhang, Ya-Ru Wang, Li-Yuan Qin, Wen-Jun Wang, Lin-Hua Yang
Bruton's tyrosine kinase inhibitors (BTKi) exhibit superior efficacy in relapsed/refractory primary central nervous system lymphoma (PCNSL), but few studies have evaluated patients with newly diagnosed PCNSL, and even fewer studies have evaluated differences in efficacy between treatment with BTKi and traditional chemotherapy. This study retrospectively analyzed the clinical characteristics of 86 patients with PCNSL and identified predictors of poor prognosis for overall survival (OS). After excluding patients who only received palliative care, 82 patients were evaluated for efficacy and survival...
May 18, 2024: Annals of Hematology
https://read.qxmd.com/read/38589646/efficacy-of-delayed-pegfilgrastim-administration-following-consolidation-therapy-with-high-dose-cytarabine-hidac-in-acute-myeloid-leukemia-aml-patients
#4
JOURNAL ARTICLE
Spencer K Yingling, Joshua Francis, Kelsea Seago, Salah Ud Din Safi, Sijin Wen, Aaron Cumpston
PURPOSE: To study the effects of delaying pegfilgrastim administration following high-dose cytarabine (HiDAC) consolidation in AML patients on time to neutrophil count recovery, infectious complications, and survival. METHODS: Single-center retrospective chart review of 55 patients receiving pegfilgrastim as early administration (within 72 h) or delayed administration (after 72 h) of HiDAC. RESULTS: The difference in neutrophil recovery time was similar between the early and delayed groups (18 days versus 19 days, p < 0...
April 9, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38428696/effects-of-prognostic-communication-strategies-on-prognostic-perceptions-treatment-decisions-and-end-of-life-anticipation-in-advanced-cancer-an-experimental-study-among-analogue-patients
#5
JOURNAL ARTICLE
Naomi C A van der Velden, Ellen M A Smets, Liesbeth M van Vliet, Linda Brom, Hanneke W M van Laarhoven, Inge Henselmans
CONTEXT: Evidence-based guidance for oncologists on how to communicate prognosis is scarce. OBJECTIVES: To investigate the effects of prognostic communication strategies (prognostic disclosure vs. communication of unpredictability vs. non-disclosure; standard vs. standard and best-case vs. standard, best- and worst-case survival scenarios; numerical vs. word-based estimates) on prognostic perceptions, treatment decision-making and end-of-life anticipation in advanced cancer...
February 28, 2024: Journal of Pain and Symptom Management
https://read.qxmd.com/read/38400942/continuous-timely-monitoring-of-core-temperature-with-two-wearable-devices-in-pediatric-patients-undergoing-chemotherapy-for-cancer-a-comparison-study
#6
JOURNAL ARTICLE
Christa Koenig, Roland A Ammann, Christine Schneider, Johanna Wyss, Jochen Roessler, Eva Brack
PURPOSE: Pediatric patients with cancer often develop chemotherapy-induced fever in neutropenia (FN), requiring emergency broad-spectrum antibiotics. Continuous temperature monitoring can lead to earlier FN detection and therapy with improved outcomes. We aimed to compare the feasibility of continuous core temperature monitoring with timely data availability between two wearable devices (WDs) in pediatric oncology patients undergoing chemotherapy. METHODS: In this prospective observational two-center study, 20 patients (median age: 8 years) undergoing chemotherapy simultaneously wore two WDs (CORE®, Everion®) for 14 days...
February 24, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38398112/association-between-inappropriate-end-of-life-cancer-care-and-specialist-palliative-care-a-retrospective-observational-study-in-two-acute-care-hospitals
#7
JOURNAL ARTICLE
Manon S Boddaert, Heidi P Fransen, Ellen J M de Nijs, Dagmar van Gerven, Leontine E A Spierings, Natasja J H Raijmakers, Yvette M van der Linden
A substantial number of patients with life-threatening illnesses like cancer receive inappropriate end-of-life care. Improving their quality of end-of-life care is a priority for patients and their families and for public health. To investigate the association between provision, timing, and initial setting of hospital-based specialist palliative care and potentially inappropriate end-of-life care for patients with cancer in two acute care hospitals in the Netherlands, we conducted a retrospective observational study using hospital administrative databases...
February 8, 2024: Cancers
https://read.qxmd.com/read/38395634/the-uk-divide-does-having-a-pembrolizumab-chemotherapy-option-in-head-and-neck-cancer-matter-real-world-experience-of-first-line-palliative-pembrolizumab-monotherapy-and-pembrolizumab-chemotherapy-combination-in-scotland
#8
JOURNAL ARTICLE
A Thapa, A Cowell, A Peters, D J Noble, A James, C Lamb, D Grose, S Vohra, S Schipani, K Mactier, J Mackenzie, D Srinivasan, K Laws, R Moleron, P Niblock, F-Y Soh, C Paterson, C Wilson
AIMS: The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence, who approved monotherapy alone in England and Wales. The aim of this study was to provide real-world performance data for first-line pembrolizumab-containing treatments for head and neck squamous cell carcinoma in the palliative setting in Scotland...
February 12, 2024: Clinical Oncology: a Journal of the Royal College of Radiologists
https://read.qxmd.com/read/38307372/identification-of-a-higher-risk-lymphedema-phenotype-and-associations-with-cytokine-gene-polymorphisms
#9
JOURNAL ARTICLE
Christine Miaskowski, Yvette P Conley, Bruce A Cooper, Steven M Paul, Betty J Smoot, Marilyn J Hammer, Mei Fu, Jon D Levine
CONTEXT: Breast cancer-related lymphedema (BCRL) is chronic condition that occurs in 5% to 75% of women following treatment for breast cancer. However, little is known about the risk factors and mechanisms associated with a worse BCRL profile. OBJECTIVES: Identify distinct BCRL profiles in women with the condition (i.e., lower versus higher risk phenotype) and evaluate for associations with pro- and anti-inflammatory genes. METHODS: Latent class profile analysis (LCPA) was used to identify the BCRL profiles using phenotypic characteristics evaluated prior to surgery...
January 31, 2024: Journal of Pain and Symptom Management
https://read.qxmd.com/read/38160047/yoga-versus-ipad-active-control-for-fatigue-in-paediatric-cancer-therapy-a-randomised-controlled-trial
#10
JOURNAL ARTICLE
Tal Schechter, Cassandra Tardif-Theriault, Nicole Culos-Reed, Victor Lewis, Andrea Orsey, Caroline Diorio, George A Tomlinson, Lillian Sung
OBJECTIVES: The primary objective was to determine if individualised yoga for hospitalised children receiving intensive chemotherapy was associated with less fatigue using the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL MFS) compared with iPad control. METHODS: This was a multicentre randomised controlled trial of individualised yoga in paediatric patients aged 8-18 years who were inpatients receiving intensive chemotherapy for leukaemia, lymphoma or haematopoietic cell transplantation...
December 30, 2023: BMJ Supportive & Palliative Care
https://read.qxmd.com/read/38123959/effects-of-early-exposure-to-palliative-care-on-end-of-life-outcomes-in-patients-with-cancer-in-a-community-setting
#11
JOURNAL ARTICLE
Ellie Fratt, Eric C Haupt, Susan E Wang, Huong Nguyen
OBJECTIVE: Although prior studies show that exposure to early outpatient palliative care (OPC) versus no exposure is associated with improved outcomes at the end of life (EoL) for patients with cancer, few examined the impact of exposure to OPC prior to home-based palliative care (HBPC) on EoL outcomes. This study compares the effect of OPC prior to HBPC versus HBPC alone on EoL outcomes in patients with cancer. METHODS: A secondary analysis of data from a trial comparing two models of HBPC was performed on patients with primary cancer diagnoses...
December 9, 2023: BMJ Supportive & Palliative Care
https://read.qxmd.com/read/38054270/cost-effectiveness-of-olaparib-plus-bevacizumab-versus-bevacizumab-monotherapy-in-the-maintenance-of-patients-with-homologous-recombination-deficiency-positive-advanced-ovarian-cancer-after-response-to-first-line-platinum-based-chemotherapy
#12
JOURNAL ARTICLE
Sergio Cedillo, Carla Garí, Susana Aceituno, Luis Manso, Ana Cristina Cercos Lleti, Pedro Ventayol Bosch, Antonio Casado, Alejandro Perez Fidalgo
OBJECTIVE: The PAOLA-1 trial confirmed that adding olaparib to bevacizumab significantly increased clinical benefit following response to platinum-based chemotherapy in homologous recombination deficiency-positive ovarian cancer. The objective of this analysis was to determine the cost-effectiveness of olaparib plus bevacizumab compared with bevacizumab alone as maintenance treatment for patients with homologous recombination deficiency-positive advanced ovarian cancer from the Spanish National Health System perspective...
December 2, 2023: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38025841/anticancer-drugs-compared-to-no-anticancer-drugs-in-patients-with-advanced-hepatobiliary-cancer-a-mapping-review-and-evidence-gap-map
#13
REVIEW
Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, Roberto Acosta-Dighero, Josefina Salazar, Marilina Santero, Adriana-G Meade, María Jesús Quintana, Gerardo Rodríguez-Grijalva, Anna Selva, Ivan Solà, Gerard Urrútia, Xavier Bonfill Cosp
INTRODUCTION: Despite being commonly recommended, the impact of anticancer drugs (ACDs) on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) may not have been sufficiently assessed. We aim to identify and map the evidence regarding ACDs versus best supportive care (BSC) for advanced HBCs, considering patient-centered outcomes. METHODS: In this mapping review, we included systematic reviews, randomized controlled trials, quasi-experimental, and observational studies comparing ACDs (chemotherapy, immunotherapy, biological/targeted therapy) versus BSC for advanced HBCs...
2023: Clinical Epidemiology
https://read.qxmd.com/read/38012456/anxiety-in-oncology-outpatients-is-associated-with-perturbations-in-pathways-identified-in-anxiety-focused-network-pharmacology-research
#14
JOURNAL ARTICLE
Kate Oppegaard, Kord M Kober, Carolyn Harris, Joosun Shin, Lisa Morse, Alejandra Calvo-Schimmel, Steven M Paul, Bruce A Cooper, Yvette P Conley, Marilyn Hammer, Vasuda Dokiparthi, Jon D Levine, Christine Miaskowski
PURPOSE: Evaluate for perturbed signaling pathways associated with subgroups of patients with low versus high levels of state anxiety. These pathways were compared to the pathways identified across eight network pharmacology studies of the anxiolytic effect(s) of a variety of compounds. METHODS: Adult outpatients had a diagnosis of breast, gastrointestinal, gynecological, or lung cancer; had received chemotherapy within the preceding four weeks; and were scheduled to receive at least two additional cycles of chemotherapy...
November 28, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38009656/a-comparison-of-the-outcomes-of-pulmonary-versus-extrapulmonary-extensive-stage-small-cell-carcinoma
#15
JOURNAL ARTICLE
Emily Chen, Po Y Yip, Annette Tognela, Geovanny Gandy, Clare Earl, Patrick Tran, Peey-Sei Kok
BACKGROUND: Extrapulmonary small cell carcinomas (EPSCCs) are rare cancers, comprising 0.1-0.4% of all cancers. The scarcity of EPSCC studies has led current treatment strategies to be extrapolated from small cell lung cancer (SCLC), justified by analogous histological and clinical features. AIMS: We conducted a retrospective cohort study comparing the outcomes of extensive-stage (ES) SCLC and EPSCC. METHODS: Patients diagnosed with ES SCLC or EPSCC between 2010 and 2020 from four hospitals in Sydney were identified...
November 27, 2023: Internal Medicine Journal
https://read.qxmd.com/read/37988838/long-term-outcomes-of-neo-adjuvant-chemotherapy-on-borderline-resectable-oral-cavity-cancers-real-world-data-of-3266-patients-and-implications-for-clinical-practice
#16
RANDOMIZED CONTROLLED TRIAL
Vanita Noronha, Aditya Dhanawat, Vijay Maruti Patil, Nandini Menon, Ajay Kumar Singh, Pankaj Chaturvedi, Prathamesh Pai, Devendra Chaukar, Sarbani Ghosh Laskar, Kumar Prabhash
BACKGROUND: Neo-adjuvant chemotherapy (NACT) followed by response assessment is the standard treatment algorithm for locally advanced oral cavity squamous cell carcinomas (OCSCC) in the Indian subcontinent. The 3-drug NACT regimen (Docetaxel-Cisplatin-5-FU) has shown improvement in overall survival over 2-drug regimen (Docetaxel-Cisplatin) in a phase-3 randomised study. We have analysed the 10-year outcomes with this treatment algorithm. METHODS: This was an institutional review board approved retrospective analysis of a prospectively collected dataset of borderline resectable OCSCC patients who underwent NACT...
January 2024: Oral Oncology
https://read.qxmd.com/read/37847317/a-pilot-randomized-placebo-controlled-double-blind-study-of-omega-3-fatty-acids-to-prevent-paclitaxel-associated-acute-pain-syndrome-in-breast-cancer-patients-alliance-a22_pilot2
#17
RANDOMIZED CONTROLLED TRIAL
Bernard Tawfik, Zoneddy R Dayao, Ursa Abigail Brown-Glaberman, V Shane Pankratz, Jacqueline M Lafky, Charles L Loprinzi, Debra L Barton
PURPOSE: Paclitaxel is associated with an acute pain syndrome (P-APS- and chronic chemotherapy-induced peripheral neuropathy (CIPN). P-APS is associated with higher risk of CIPN. Omega-3 fatty acids have well-established anti-inflammatory and neuroprotective properties. The primary purpose of this pilot study was to assess whether omega-3 fatty acids could decrease P-APS and thus CIPN. METHODS: Patients scheduled to receive weekly paclitaxel for breast cancer were randomized to receive 4 g of omega-3 acid ethyl esters (Lovaza) or placebo, beginning 1 week prior and continued until paclitaxel was stopped...
October 17, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/37657725/radiation-therapy-in-the-last-month-of-life-association-with-aggressive-care-at-the-end-of-life
#18
JOURNAL ARTICLE
Mellar P Davis, Erin Vanenkevort, Amanda Young, Mark Wojtowicz, Mudit Gupta, Braxton Lagerman, Edward Liu, Heath Mackley, Rajiv Panikkar
CONTEXT: Half of the patients with cancer who undergo radiation therapy do so with palliative intent. OBJECTIVES: To determine the proportion of undergoing radiation in the last month of life, patient characteristics, cancer course, the type and duration of radiation, whether palliative care was involved, and the of radiation with aggressive cancer care metrics. METHODS: One thousand seven hundred twenty-seven patients who died of cancer between January 1, 2018, and December 31, 2019, were included...
December 2023: Journal of Pain and Symptom Management
https://read.qxmd.com/read/37611540/metastatic-and-malignant-phyllodes-tumors-of-the-breast-an-update-for-current-management
#19
REVIEW
Brandon Goodwin, Adejumoke Fisayo Oyinlola, Meejan Palhang, Danielle Lehman, Rebecca Platoff, Umur Atabek, Francis Spitz, Young Hong
Metastatic, malignant phyllodes tumor (PT) of the breast is a rare and aggressive neoplasm. Currently, there is no agreed upon consensus as to best management practices. A systematic review of literature was conducted investigating surgical, chemotherapeutic, and radiotherapeutic management for metastatic PT. Databases employed to identify articles included Embase, PubMed, and SAGE Journals. Diagnosis of metastatic PT has been of significant difficulty to radiologists as it is often confused with fibroadenomas...
August 23, 2023: American Surgeon
https://read.qxmd.com/read/37573294/treatment-with-anticancer-drugs-for-advanced-pancreatic-cancer-a-systematic-review
#20
JOURNAL ARTICLE
Josefina Salazar, Javier Bracchiglione, Olga Savall-Esteve, Alba Antequera, David Bottaro-Parra, Marta Gutiérrez-Valencia, Susana Martínez-Peralta, Carles Pericay, Ariadna Tibau, Xavier Bonfill
BACKGROUND: Patients with advanced pancreatic cancer have a poor prognosis and high burden of cancer-related symptoms. It is necessary to assess the trade-off of clinical benefits and possible harms of treatments with anticancer drugs (TAD). This systematic review aims to compare the effectiveness of TAD versus supportive care or no treatment, considering all patient-important outcomes. METHODS: We searched PubMed, Embase, Cochrane Library, and Epistemonikos...
August 12, 2023: BMC Cancer
keyword
keyword
65280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.